Neuroprotective effects of metformin against Aβ-mediated inhibition of long-term potentiation in rats fed a high-fat diet

Brain Research Bulletin

Volumn 121, Issue , 2016, Pages 178-185

  Asadbegi, Masoumeh ^a   Yaghmaei, Parichehreh ^a   Salehi, Iraj ^b   Ebrahim Habibi, Azadeh ^c   Komaki, Alireza ^b,d  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Alzheimer's disease; High fat diet; Hippocampus; Long term potentiation; Metformin; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; METFORMIN; TRIACYLGLYCEROL; URETHAN; VERY LOW DENSITY LIPOPROTEIN; AMYLOID BETA-PROTEIN (1-42); LIPID; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT;

ADULT; AMPLITUDE MODULATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DENTATE GYRUS; ELECTRIC POTENTIAL; ELECTRODE IMPLANTATION; ELECTROPHYSIOLOGICAL PROCEDURES; ENZYME INHIBITION; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPUS; IN VIVO STUDY; LIPID DIET; LONG TERM POTENTIATION; MALE; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SPIKE; STEREOTACTIC DEVICE; TRIACYLGLYCEROL BLOOD LEVEL; ADVERSE EFFECTS; ALZHEIMER DISEASE; ANIMAL; BIOPHYSICS; BLOOD; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; ELECTROSTIMULATION; EVOKED RESPONSE; LIPID METABOLISM; WISTAR RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BIOPHYSICS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ELECTRIC STIMULATION; EVOKED POTENTIALS; LIPID METABOLISM; LIPIDS; LONG-TERM POTENTIATION; MALE; METFORMIN; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR;

EID: 84958178209     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2016.02.005     Document Type: Article

References (115)

1. Ashabi G., et al. Activation of AMP-activated protein kinase by metformin protects against global cerebral ischemia in male rats: interference of AMPK/PGC-1α pathway. Metab. Brain Dis. 2014, 29:47-58.
2. Ashabi G., et al. Pre-treatment with metformin activates Nrf2 antioxidant pathways and inhibits inflammatory responses through induction of AMPK after transient global cerebral ischemia. Metab. Brain Dis. 2015, 30:747-754.
3. Banas S.M., et al. A dietary fat excess alters metabolic and neuroendocrine responses before the onset of metabolic diseases. Cell. Mol. Neurobiol. 2009, 29:157-168.
4. Barron, A.M., et al., 2013. Sex-specific effects of high fat diet on indices of metabolic syndrome in 3xTg-AD mice: implications for Alzheimer's disease.
5. Bartsch T., Wulff P. The hippocampus in aging and disease: from plasticity to vulnerability. Neuroscience 2015, 309:1-16.
6. Barzilai N., Gabriely I. The role of fat depletion in the biological benefits of caloric restriction. J. Nutr. 2001, 131:903S-906S.
7. Bear M., Linden D. The mechanisms and meaning of long-term synaptic depression in the mammalian brain. Synapses 2001, 1:455-517.
8. Beeri M., et al. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology 2008, 71:750-757.
9. Belabed L., et al. Impairment of lymphocyte function in head-injured rats: effects of standard and immune-enhancing diets for enteral nutrition. Clin. Nutr. 2006, 25:832-841.
10. Beydoun M., Beydoun H., Wang Y. Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. Obes. Rev. 2008, 9:204-218.
11. Bliss T.V., Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993, 361:31-39.
12. Cai Z., Yan Y., Wang Y. Minocycline alleviates beta-amyloid protein and tau pathology via restraining neuroinflammation induced by diabetic metabolic disorder. Clin. Interv. Aging 2013, 8:1089.
13. Chen Y., et al. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3907-3912.
14. Chung M.-M., et al. The neuroprotective role of metformin in advanced glycation end product treated human neural stem cells is AMPK-dependent. Biochim. Biophys. Acta 2015, 1852:720-731.
15. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983, 219:1184-1190.
16. Dalla Y., et al. Memory restorative role of statins in experimental dementia: an evidence of their cholesterol dependent and independent actions. Pharmacol. Rep. 2010, 62:784-796.
17. Davis J.F., et al. Exposure to elevated levels of dietary fat attenuates psychostimulant reward and mesolimbic dopamine turnover in the rat. Behav. Neurosci. 2008, 122:1257.
18. DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med. 1999, 131:281-303.
19. de Melo C.L., et al. Oleanolic acid: a natural triterpenoid improves blood glucose tolerance in normal mice and ameliorates visceral obesity in mice fed a high-fat diet. Chem. Biol. Interact. 2010, 185:59-65.
20. Eleftheriadou I., et al. The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism. Curr. Diabetes Rev. 2008, 4:340-356.
21. Elias M., et al. Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int. J. Obes. 2003, 27:260-268.
22. Eskelinen M.H., et al. Fat intake at midlife and cognitive impairment later in life: a population-based CAIDE study. Int. J. Geriatr. Psychiatry 2008, 23:741-747.
23. Estadella D., et al. Effect of palatable hyperlipidic diet on lipid metabolism of sedentary and exercised rats. Nutrition 2004, 20:218-224.
24. Farr S.A., et al. Obesity and hypertriglyceridemia produce cognitive impairment. Endocrinology 2008, 149:2628-2636.
25. Fitzpatrick A.L., et al. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch. Neurol. 2009, 66:336-342.
26. Flegal K.M., et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303:235-241.
27. Fogarty S., Hardie D. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim. Biophys. Acta 2010, 1804:581-591.
28. Gáspárová Z., Šnirc V., Štolc S. The new pyridoindole antioxidant SMe1EC2 and its intervention in hypoxia/hypoglycemia-induced impairment of long-term potentiation in rat hippocampus. Interdiscip. Toxicol. 2011, 4:56-61.
29. Gahete M.D., et al. Role of ghrelin system in neuroprotection and cognitive functions: implications in Alzheimer's disease. Peptides 2011, 32:2225-2228.
30. Galili O., et al. Early experimental obesity is associated with coronary endothelial dysfunction and oxidative stress. Am. J. Physiol. 2007, 292:H904-H911.
31. Ghahremanitamadon F., et al. Protective effects of borago officinalis extract on amyloid β-Peptide (25-35)-Induced memory impairment in male rats: a behavioral study. BioMed Res. Int. 2014, 2014.
32. Glueck C., et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 2001, 50:856-861.
33. Grant W.B. Dietary links to Alzheimer's disease. Alzheimer Dis Rev. 1997, 2:42-55.
34. Guarente L., Picard F. Calorie restriction-the SIR2 connection. Cell 2005, 120:473-482.
35. Gupta A., Bisht B., Dey C.S. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 2011, 60:910-920.
36. Gustafson D., et al. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch. Intern. Med. 2003, 163:1524-1528.
37. Henderson V.W. Alzheimer's disease: review of hormone therapy trials and implications for treatment and prevention after menopause. J. steroid Biochem. Mol. Biol. 2014, 142:99-106.
38. Hernández-Zimbrón L., Rivas-Arancibia S. Oxidative stress caused by ozone exposure induces β-amyloid 1-42 overproduction and mitochondrial accumulation by activating the amyloidogenic pathway. Neuroscience 2015, 304:340-348.
39. Hettich, M.M., et al., 2014. The anti-diabetic drug metformin reduces BACE1 protein level by interfering with the MID1 complex.
40. Holmes C. Review: systemic inflammation and Alzheimer's disease. Neuropathol. Appl. Neurobiol. 2013, 39:51-68.
41. Hopps E., et al. A novel component of the metabolic syndrome: the oxidative stress. Nutrition. Metab, Cardiovasc, Dis. 2010, 20:72-77.
42. Hwang L.L., et al. Sex differences in high-fat diet-induced obesity, metabolic alterations and learning: and synaptic plasticity deficits in mice. Obesity 2010, 18:463-469.
43. Imfeld P., et al. Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study. J. Am. Geriatr. Soc. 2012, 60:916-921.
44. Kaczmarczyk M.M., et al. Methylphenidate prevents high-fat diet (HFD)-induced learning/memory impairment in juvenile mice. Psychoneuroendocrinology 2013, 38:1553-1564.
45. Karamian R., Komaki A., Salehi I., Tahmasebi L., Komaki H., Shahidi S., Sarihi A. Vitamin C reverses lead-induced deficits in hippocampal synaptic plasticity in rats. Brain Res. Bull. 2015, 116:7-15.
46. Karimi S.A., et al. Effect of high-fat diet and antioxidants on hippocampal long-term potentiation in rats: an in vivo study. Brain Res. 2013, 1539:1-6.
47. Karimi S.A., et al. Role of group II metabotropic glutamate receptors (mGluR2/3) blockade on long-term potentiation in the dentate gyrus region of hippocampus in rats fed with high-Fat diet. Neurochem. Res. 2015, 40:811-817.
48. Khang R., Park C., Shin J.-H. The biguanide metformin alters phosphoproteomic profiling in mouse brain. Neurosci. Lett. 2014, 579:145-150.
49. Kickstein E., et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21830-21835.
50. Kim H.G., et al. Mori folium and mori fructus mixture attenuates high-Fat diet-Induced cognitive deficits in mice. Evid.-Based Complement. Altern. Med. 2015, 2015.
51. Knight E.M., et al. High-fat diet-induced memory impairment in triple-transgenic Alzheimer's disease (3xTgAD) mice is independent of changes in amyloid and tau pathology. Neurobiol. Aging 2014, 35:1821-1832.
52. Komaki A., et al. Effects of exposure to an extremely low frequency electromagnetic field on hippocampal long-term potentiation in rat. Brain Res. 2014, 1564:1-8.
53. Koubova J., Guarente L. How does calorie restriction work?. Genes Dev. 2003, 17:313-321.
54. Kumar A., et al. Silymarin ameliorates memory deficits and neuropathological changes in mouse model of high-fat-diet-induced experimental dementia. Naunyn Schmiedebergs Arch. Pharmacol. 2014, 387:777-787.
55. Laitinen M., et al. Fat intake at midlife and risk of dementia and Alzheimer's disease: a population-based study. Dement. Geriatr. Cogn. Disord. 2006, 22:99-107.
56. Lane M.A., et al. Effects of long-term diet restriction on aging and longevity in primates remain uncertain. J. Gerontol. Ser. A: Biol. Sci. Med. Sci. 2004, 59:B405-B407.
57. Lindqvist A., et al. High-fat diet impairs hippocampal neurogenesis in male rats. Eur. J. Neurol. 2006, 13:1385-1388.
58. Liu Z., et al. High-Fat diet induces hepatic insulin resistance and impairment of synaptic plasticity. PLoS One 2015, 10:e0128274.
59. Lorenzo A., Yankner B.A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:12243-12247.
60. Luchsinger J.A., et al. Caloric intake and the risk of Alzheimer disease. Arch. Neurol. 2002, 59:1258-1263.
61. Ma T.C., et al. Metformin therapy in a transgenic mouse model of Huntington's disease. Neurosci. Lett. 2007, 411:98-103.
62. Martin S.A., et al. Maternal high-Fat diet worsens memory deficits in the triple-transgenic (3xTgAD) mouse model of Alzheimer's disease. PLoS One 2014, 9:e99226.
63. Masoro E.J. Caloric restriction and aging: an update. Exp. Gerontol. 2000, 35:299-305.
64. Masoro E.J. Overview of caloric restriction and ageing. Mech. Ageing Dev. 2005, 126:913-922.
65. McNeilly A., et al. A high-fat-diet-induced cognitive deficit in rats that is not prevented by improving insulin sensitivity with metformin. Diabetologia 2012, 55:3061-3070.
66. Mecocci P., MacGarvey U., Beal M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 1994, 36:747-751.
67. Miller A.A., Spencer S.J. Obesity and neuroinflammation: a pathway to cognitive impairment. Brain Behav. Immu. 2014, 42:10-21.
68. Mobley C.B., et al. Effects of protein type and composition on postprandial markers of skeletal muscle anabolism, adipose tissue lipolysis, and hypothalamic gene expression. J. Int. Soc. Sports Nutr. 2015, 12:14.
69. Mody N., et al. Susceptibility to diet-induced obesity and glucose intolerance in the APP SWE/PSEN1 A246E mouse model of Alzheimer's disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein. Diabetologia 2011, 54:2143-2151.
70. Morgan S., Teyler T. VDCCs and NMDARs underlie two forms of LTP in CA1 hippocampus in vivo. J. Neurophysiol. 1999, 82:736-740.
71. Moroz N., et al. Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J. Alzheimers Dis. 2008, 15:29-44.
72. Morris M.C., Tangney C.C. Dietary fat composition and dementia risk. Neurobiol. Aging 2014, 35:S59-S64.
73. Morris R.G., et al. Elements of a neurobiological theory of the hippocampus: the role of activity-dependent synaptic plasticity in memory. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2003, 358:773-786.
74. Moy G.A., McNay E.C. Caffeine prevents weight gain and cognitive impairment caused by a high-fat diet while elevating hippocampal BDNF. Physiol. Behav. 2013, 109:69-74.
75. Nuzzo D., et al. Insulin resistance as common molecular denominator linking obesity to Alzheimer's disease. Curr. Alzheimer Res. 2015, 12:723-735.
76. Panza F., et al. Mediterranean diet and cognitive decline. Public Health Nutr. 2004, 7:959-963.
77. Parle, M., Singh, N., 2007. Reversal of memory deficits by atorvastatin and simvastatin in rats, 127, 1125-1137.
78. Partridge L., Piper M.D., Mair W. Dietary restriction in drosophila. Mech. Ageing Dev. 2005, 126:938-950.
79. Pathan A.R., et al. Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sci. 2006, 79:2209-2216.
80. Pathan A.R., et al. Rosiglitazone attenuates the cognitive deficits induced by high fat diet feeding in rats. Eur. J. Pharmacol. 2008, 589:176-179.
81. Paxinos G., Watson C. The Brain in the Stereotaxis Coordinates 2006, Academic Press, San Diago, New York, (Vol., ed.^eds.).
82. Paxinos G., et al. Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex: strain and weight. J. Neurosci. Methods 1985, 13:139-143.
83. Peng D., et al. Hyperphosphorylation of tau protein in hippocampus of central insulin-resistant rats is associated with cognitive impairment. Cell. Physiol. Biochem. 2013, 32:1417-1425.
84. Pintana H., et al. Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats. Life Sci. 2012, 91:409-414.
85. Porter D., et al. Actions of incretin metabolites on locomotor activity: cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice. Peptides 2012, 35:1-8.
86. Poucet B., et al. The hippocampus and the neural code of spatial memory. Biol. J. 2009, 204:103-112.
87. Profenno L.A., Porsteinsson A.P., Faraone S.V. Meta-analysis of Alzheimer's disease risk with obesity diabetes, and related disorders. Biol. Psychiatry 2010, 67:505-512.
88. Reinehr T., et al. Insulin sensitivity among obese children and adolescents: according to degree of weight loss. Pediatrics 2004, 114:1569-1573.
89. Rojas L., Gomes M.B. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol. Metab. Syndr. 2013, 5:6.
90. Salehi I., Karamian R., Komaki A., Tahmasebi L., Taheri M., Nazari M., Shahidi S., Sarihi A. Effects of vitamins E on lead-induced impairments in hippocampal synaptic plasticity. Brain Res. 2015, 1629:270-281.
91. Salminen A., et al. AMP-activated protein kinase: a potential player in Alzheimer's disease. J. Neurochem. 2011, 118:460-474.
92. Sant'Diniz Y., et al. Monosodium glutamate in standard and high-fiber diets: metabolic syndrome and oxidative stress in rats. Nutrition 2005, 21:749-755.
93. Sarkaki A., et al. Metformin improves anxiety-like behaviors through AMPK-dependent regulation of autophagy following transient forebrain ischemia. Metab. Brain Dis. 2015, 1-12.
94. Schneider J.A., et al. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann. Neurol. 2009, 66:200-208.
95. Sodhi R.K., Singh N. Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet. PLoS One 2013, 8:e70487.
96. Squire L.R. Memory and the hippocampus: a synthesis from findings with rats, monkeys, and humans. Psychol. Rev. 1992, 99:195.
97. Steinberg G.R., Kemp B.E. AMPK in health and disease. Physiol. Rev. 2009, 89:1025-1078.
98. Stouffer E.M., Warninger E.E., Michener P.N. A high-fat diet impairs learning that is dependent on the dorsal hippocampus but spares other forms of learning. Hippocampus 2015, 25:1567-1576.
99. Stranahan A.M., Mattson M.P. Impact of energy intake and expenditure on neuronal plasticity. Neuromol. Med. 2008, 10:209-218.
100. Stranahan A.M., et al. Diet-induced elevations in serum cholesterol are associated with alterations in hippocampal lipid metabolism and increased oxidative stress. J. Neurochem. 2011, 118:611-615.
101. Tahmasebi L., et al. The interactive role of cannabinoid and vanilloid systems in hippocampal synaptic plasticity in rats. Eur. J. Pharmacol. 2015, 757:68-73.
102. Taube J., Schwartzkroin P. Mechanisms of long-term potentiation EPSP/spike dissociation, intradendritic recordings, and glutamate sensitivity. J. Neurosci. 1988, 8:1632-1644.
103. Teyler T., DiScenna P. Long-term potentiation. Annu. Rev. Neurosci. 1987, 10:131-161.
104. Teyler T.J., et al. Synaptic plasticity and secondary epileptogenesis. Int. Rev. Neurobiol. 2001, 253-268.
105. Van Den Berg E., et al. Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: a systematic comparison of their impact on cognition. Biochim. Biophys. Acta 2009, 1792:470-481.
106. Vandal M., et al. Insulin reverses the high-fat diet-induced increase in brain Aβ and improves memory in an animal model of Alzheimer disease. Diabetes 2014, 63:4291-4301.
107. Vargas-Robles H., et al. Antioxidative diet supplementation reverses high-Fat diet-Induced increases of cardiovascular risk factors in mice. Oxid. Med. Cell. Longevity 2015, 2015.
108. Vinters H.V. Emerging concepts in alzheimer's disease. annual review of pathology. Mech. Dis. 2015, 10:291-319.
109. Walker G., et al. Dietary restriction in C: elegans: from rate-of-living effects to nutrient sensing pathways. Mech. Ageing Dev. 2005, 126:929-937.
110. Wang J., et al. Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell 2012, 11:23-35.
111. Whitmer R.A., et al. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 2005, 330:1360.
112. Willy C., et al. Impact of vitamin E supplement in standard laboratory animal diet on microvascular manifestation of ischemia/reperfusion injury. Free Radic. Biol. Med. 1995, 19:919-926.
113. Yaghmaei P., et al. Indole and trans-chalcone attenuate amyloid β plaque accumulation in male Wistar rat: in vivo effectiveness of two anti-amyloid scaffolds. Arch. Ital. Biol. 2013, 151:106-113.
114. Zargooshnia S., et al. The protective effect of Borago Officinalis extract on amyloid β (25-35)-induced long term potentiation disruption in the dentate gyrus of male rats. Metab. Brain Dis. 2015, 30:151-156.
115. Zheng Z., et al. Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes 2012, 61:217-228.